Literature DB >> 10738117

Reduced expression of p27(Kip1) correlates with an early stage of cancer invasion in oral squamous cell carcinoma.

Y Kudo1, T Takata, I Ogawa, M Zhao, S Sato, T Takekoshi, M Miyauchi, H Nikai.   

Abstract

Down-regulation of p27(Kip1) has been reported to correlate with poor survival of various carcinoma patients including oral squamous cell carcinomas (OSCCs). It is still unclear, however, at what stage of oral carcinogenesis the down-regulation of this protein occurs. In this study, therefore, we evaluated immunoexpression of p27(Kip1) protein in 17 cases of oral epithelial dysplasia and succeeding invasive OSCC in the same patient. We reported here that 88% cases showed high p27(Kip1) expression in dysplastic lesions, whereas 82% cases of succeeding invasive OSCC exhibited reduced expression. The reduction of p27(Kip1) expression was also observed in 16 of 19 (84%) early invasive lesions and well correlated with Ki-67 expression which is good indicator of cell proliferation. We also investigated immunoexpression of p53 protein of which abnormality has been known to occur during the early stage of OSCC development. Overexpression of p53 protein was demonstrated in 29% of dysplastic lesions, 42% of early invasive and 71% of invasive OSCCs. These findings suggest that abnormalities of both p53 and p27(Kip1) are involved in the carcinogenesis of OSCC, but they seem to play their role at different stages of oral cancer development, respectively. Reduced expression of p27(Kip1) may concern the cancer invasion directly or indirectly as well as abnormal proliferation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738117     DOI: 10.1016/s0304-3835(99)00419-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Absence of human papillomavirus in tonsillar squamous cell carcinomas from Chinese patients.

Authors:  Wei Li; Carol H Thompson; Ding Xin; Yvonne E Cossart; Christopher J O'Brien; Edward B McNeil; Kan Gao; Richard A Scolyer; Barbara R Rose
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

2.  Genetic variants of p27 and p21 as predictors for risk of second primary malignancy in patients with index squamous cell carcinoma of head and neck.

Authors:  Zhongqiu Wang; Erich M Sturgis; Fenghua Zhang; Dapeng Lei; Zhensheng Liu; Li Xu; Xicheng Song; Qingyi Wei; Guojun Li
Journal:  Mol Cancer       Date:  2012-03-26       Impact factor: 27.401

Review 3.  Can immunohistochemistry serve as an alternative to subjective histopathological diagnosis of oral epithelial dysplasia?

Authors:  Ahmad A Abdulmajeed; Camile S Farah
Journal:  Biomark Cancer       Date:  2013-10-10

4.  A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition.

Authors:  Yong Fang; Yihong Wang; Yulei Wang; Yan Meng; Junlan Zhu; Honglei Jin; Jingxia Li; Dongyun Zhang; Yonghui Yu; Xue-Ru Wu; Chuanshu Huang
Journal:  Biochem J       Date:  2014-11-01       Impact factor: 3.857

5.  p27Kip1 expression as a prognostic marker for squamous cell carcinoma of the head and neck.

Authors:  Miguel Reis DE Almeida; Mario Pérez-Sayáns; José Manuel Suárez-Peñaranda; José Manuel Somoza-Martín; Abel García-García
Journal:  Oncol Lett       Date:  2015-09-18       Impact factor: 2.967

6.  A Randomized Double-Blind Placebo-Controlled Trial of Fruit and Vegetable Concentrates on Intermediate Biomarkers in Head and Neck Cancer.

Authors:  Mridul Datta; Edward G Shaw; Glenn J Lesser; L Douglas Case; Mara Z Vitolins; Charles Schneider; Bart Frizzell; Christopher Sullivan; Mark Lively; Elizabeth Franzmann; Jennifer J Hu
Journal:  Integr Cancer Ther       Date:  2017-01-19       Impact factor: 3.279

7.  Immunohistochemical evaluation of oral epithelial dysplasia using cyclin-D1, p27 and p63 expression as predictors of malignant transformation.

Authors:  Abilasha Ramasubramanian; Pratibha Ramani; Herald J Sherlin; Priya Premkumar; Anuja Natesan; Chandrasekar Thiruvengadam
Journal:  J Nat Sci Biol Med       Date:  2013-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.